Cambridge Trust Co. raised its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 0.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,712 shares of the medical instruments supplier’s stock after buying an additional 333 shares during the period. Becton Dickinson and comprises approximately 1.8% of Cambridge Trust Co.’s portfolio, making the stock its 18th largest position. Cambridge Trust Co.’s holdings in Becton Dickinson and were worth $30,645,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. IMS Capital Management bought a new position in shares of Becton Dickinson and during the third quarter valued at approximately $29,000. Oregon Public Employees Retirement Fund increased its stake in shares of Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares in the last quarter. RPG Investment Advisory LLC bought a new position in shares of Becton Dickinson and during the first quarter valued at approximately $32,000. Nalls Sherbakoff Group LLC bought a new position in shares of Becton Dickinson and during the fourth quarter valued at approximately $34,000. Finally, Aspire Private Capital LLC bought a new position in shares of Becton Dickinson and during the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 84.87% of the company’s stock.
In related news, CEO Vincent A. Forlenza sold 3,123 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the sale, the chief executive officer now owns 215,372 shares in the company, valued at $54,926,321.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the sale, the chief executive officer now owns 227,250 shares in the company, valued at approximately $56,903,400. The disclosure for this sale can be found here. Insiders sold 29,684 shares of company stock worth $7,518,574 in the last 90 days. 0.12% of the stock is currently owned by corporate insiders.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the company posted $2.48 earnings per share. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities analysts predict that Becton Dickinson and Co will post 12.08 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.35%. The ex-dividend date of this dividend was Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.
A number of brokerages have weighed in on BDX. Barclays raised their target price on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Zacks Investment Research cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. Finally, Morgan Stanley cut their price target on shares of Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $256.25.
ILLEGAL ACTIVITY WARNING: This article was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/22/cambridge-trust-co-has-30-65-million-holdings-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: What is the strike price in options trading?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.